American Society for Transplantation and Cellular Therapy (ASTCT)

Long-term outcomes of 63 patients with transfusion-dependent β-thalassemia (TDT) followed-up to 8 years after treatment with betibeglogene autotemcel (beti-cel) gene therapy and factors impacting neutrophil and platelet engraftment.

Authors: Olson TS.